Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.


Options:
A: Arm Label: PT003 (Dose 1); Type: EXPERIMENTAL; Interventions: Drug: PT003 | Arm Label: PT003 (Dose 2); Type: EXPERIMENTAL; Interventions: Drug: PT003 | Arm Label: PT003 (Dose 3); Type: EXPERIMENTAL; Interventions: Drug: PT003 | Arm Label: PT003 (Dose 4); Type: EXPERIMENTAL; Interventions: Drug: PT003 | Arm Label: PT003 (Dose 5); Type: EXPERIMENTAL; Interventions: Drug: PT003 | Arm Label: PT001; Type: EXPERIMENTAL; Interventions: Drug: PT001 | Arm Label: PT005; Type: EXPERIMENTAL; Interventions: Drug: PT005 | Arm Label: Spiriva® Handihaler®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium inhalation powder | Intervention Type: DRUG; Name: PT003; Assigned to Arm(s): PT003 (Dose 1), PT003 (Dose 2), PT003 (Dose 3), PT003 (Dose 4), PT003 (Dose 5) | Intervention Type: DRUG; Name: PT001; Assigned to Arm(s): PT001 | Intervention Type: DRUG; Name: PT005; Assigned to Arm(s): PT005 | Intervention Type: DRUG; Name: Tiotropium inhalation powder; Assigned to Arm(s): Spiriva® Handihaler®
B: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100mcg/Vilanterol 25mcg | Arm Label: Fluticasone Propionate/Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticaosne Propionate 500mcg/Salmeterol 50mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100mcg/Vilanterol 25mcg; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticaosne Propionate 500mcg/Salmeterol 50mcg; Assigned to Arm(s): Fluticasone Propionate/Salmeterol
C: Arm Label: Glycopyrronium bromide 50 μg; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium bromide | Arm Label: Placebo to glycopyrronium bromide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to glycopyrronium bromide | Arm Label: Tiotropium 18 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: Glycopyrronium bromide; Assigned to Arm(s): Glycopyrronium bromide 50 μg | Intervention Type: DRUG; Name: Placebo to glycopyrronium bromide; Assigned to Arm(s): Placebo to glycopyrronium bromide | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium 18 μg
D: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo

Answer: C